5 unchanged sentences
Amended and Restated Bylaws
−Removed: Second Amendment to the Exclusive Janssen License and Collaboration Agreement, dated July 27, 2021, by and between Protagonist Therapeutics, Inc.
−Removed: and Janssen Biotech, Inc.
−Removed: Arbitration Resolution Agreement, dated August 4 th , 2021, by and among Protagonist Therapeutics, Inc.
−Removed: and Zealand Pharma, A/S.
−Removed: Second Amendment to Lease, dated August 10, 2021, by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center, LP as Landlord.
+Added: Employment Offer Letter dated March 25, 2022 by and between the Registrant and Asif Al i
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
15 unchanged sentences
PROTAGONIST THERAPEUTICS, INC.
−Removed: November 3, 2021
/s/ Dinesh V.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 3, 2021
−Removed: /s/ Don Kalkofen
−Removed: Chief Financial Officer
+Added: Executive Vice President, Chief Financial Officer
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.